|
Alzheimer's Disease
|
0.680 |
Biomarker
|
disease |
BEFREE |
We interpret these observations as suggesting that uPA represents a possible candidate gene for the chromosome 10 familial AD locus.
|
12271474 |
2002 |
|
Alzheimer's Disease
|
0.680 |
Biomarker
|
disease |
BEFREE |
Our data support a role for PLAU_1 as an independent genetic risk factor for AD in the Italian population for those subjects who do not have the APOE-epsilon4 allele.
|
17174555 |
2007 |
|
Alzheimer's Disease
|
0.680 |
GeneticVariation
|
disease |
BEFREE |
No association of a non-synonymous PLAU polymorphism with Alzheimer's disease and disease-related traits.
|
15558716 |
2005 |
|
Alzheimer's Disease
|
0.680 |
Biomarker
|
disease |
BEFREE |
We have evaluated variants in seven Aβ-degrading genes (ACE, ECE1, ECE2, IDE, MME, PLAU, and TF) for association with AD risk in the Genetic and Environmental Risk in Alzheimer's Disease Consortium 1 (GERAD1) cohort, and with three cognitive phenotypes in the Lothian Birth Cohort 1936 (LBC1936), using 128 and 121 SNPs, respectively.
|
22693153 |
2012 |
|
Alzheimer's Disease
|
0.680 |
GeneticVariation
|
disease |
BEFREE |
This meta-analysis showed that T allele of rs2227564 polymorphism in PLAU gene could increase the effects on risk of AD, and this result needs to be confirmed by further studies.
|
23813610 |
2013 |
|
Alzheimer's Disease
|
0.680 |
GeneticVariation
|
disease |
BEFREE |
Previously some studies have examined the role of common variation in the PLAU gene with AD risk but the results have been inconsistent and this inconsistency could have been due to the use of relatively small sample sizes.
|
16967469 |
2007 |
|
Alzheimer's Disease
|
0.680 |
GeneticVariation
|
disease |
BEFREE |
A functional polymorphism within plasminogen activator urokinase (PLAU) is associated with Alzheimer's disease.
|
16825285 |
2006 |
|
Quebec platelet disorder
|
0.670 |
GeneticVariation
|
disease |
BEFREE |
QPD is the first bleeding disorder identified to be caused by a PLAU mutation and it is also the first bleeding disorder recognized to result from a gene copy number mutation.
|
21495923 |
2011 |
|
Quebec platelet disorder
|
0.670 |
Biomarker
|
disease |
BEFREE |
A unique gain-of-function defect in fibrinolysis causes the Quebec platelet disorder (QPD) which is characterized by profibrinolytic platelets containing increased urokinase-type plasminogen activator (uPA) in the α-granules.
|
31427261 |
2019 |
|
Quebec platelet disorder
|
0.670 |
GeneticVariation
|
disease |
BEFREE |
QPD is the first bleeding disorder to be associated with a gene duplication event and a PLAU mutation.
|
20007542 |
2010 |
|
Quebec platelet disorder
|
0.670 |
Biomarker
|
disease |
BEFREE |
QPD PLAU transcripts were consistent with reference gene models, with a much higher proportion of reads originating from the disease chromosome in megakaryocytes than granulocytes.
|
28301587 |
2017 |
|
Quebec platelet disorder
|
0.670 |
GeneticVariation
|
disease |
BEFREE |
Quebec platelet disorder (QPD) is an autosomal dominant bleeding disorder associated with increased urokinase-type plasminogen activator in platelets and alpha-granule protein degradation.
|
15026313 |
2004 |
|
Quebec platelet disorder
|
0.670 |
AlteredExpression
|
disease |
BEFREE |
Although patients with the QPD have normal to increased u-PA levels in their plasma, without evidence of systemic fibrinogenolysis, their increased platelet u-PA could contribute to bleeding by accelerating fibrinolysis within the hemostatic plug.
|
11435291 |
2001 |
|
Quebec platelet disorder
|
0.670 |
AlteredExpression
|
disease |
BEFREE |
Although QPD CD34(+) progenitors expressed normal amounts of uPA, their differentiation into megakaryocytes abnormally increased expression of the uPA gene but not the flanking genes for vinculin or calcium/calmodulin-dependent protein kinase IIgamma on chromosome 10.
|
19029443 |
2009 |
|
Myocardial Infarction
|
0.510 |
GeneticVariation
|
disease |
BEFREE |
Association of putative functional variants in the PLAU gene and the PLAUR gene with myocardial infarction.
|
20518747 |
2010 |
|
Neoplasm Metastasis
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
Stromal macrophages of different phenotypes can contribute to the expression of proteins that affects metastasis such as urokinase-type plasminogen activator (uPA), its receptor uPAR, and plasminogen activator inhibitor-1 (PAI-1), but knowledge of how essential their contribution is in comparison to the cancer cells in small cell lung cancer (SCLC) and lung squamous cell carcinoma (SCC) is lacking.
|
26050228 |
2015 |
|
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Urokinase-type plasminogen activator (uPA) is a member of the serine protease family and can break down various components of the extracellular matrix to promote growth, invasion, and metastasis of several malignancies including breast cancer.
|
12198113 |
2002 |
|
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Evidence has accumulated that urokinase-type plasminogen activator (uPA), its inhibitor (PAI-1) and receptor (uPAR) are involved in tumor invasion and metastasis.
|
9194591 |
1997 |
|
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
The urokinase-type plasminogen activator receptor (uPAR) has been implicated in tumor growth and metastasis.
|
20696135 |
2010 |
|
Neoplasm Metastasis
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
It is well documented that the binding of urokinase-type plasminogen activator (uPA) to its receptor (uPAR), which has been implicated in cancer invasion and metastasis, is regulated by several inhibitors such as maspin.
|
21833477 |
2011 |
|
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
We have also demonstrated previously that transforming growth factor-beta1 (TGF-beta1) stimulates urokinase-type plasminogen activator (uPA)-dependent invasion and metastasis of HRA cells.
|
14597629 |
2004 |
|
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Stromal cells also contribute to breast cancer growth and metastasis through the production of extracellular matrix (ECM) modifiers such as urokinase type plasminogen activator (uPA), its receptor (uPAR), its inhibitors (PAI-1 and PAI-2), matrix metalloproteinases (MMPs), and growth factors, including the fibroblast and insulin-like growth factors (FGF's and IGF's).
|
12574821 |
2003 |
|
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Taking into account the role of uPA and PAI in cell detachment, formation of new stroma, tumor cell reimplantation and metastasis uPA inhibition should be further investigated as maintenance treatment in patients with advanced EOC.
|
27345498 |
2017 |
|
Neoplasm Metastasis
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
Patients with visceral metastasis and more than one metastatic site were significantly more likely to present with elevated uPA levels.
|
30783124 |
2019 |
|
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
NF-kappaB-mediated expression of genes involved in angiogenesis (IL-8, VEGF), and invasion and metastasis (MMP9, uPA, uPA receptor) may further contribute to the progression of prostate cancer.
|
14689584 |
2004 |